tbuckley/cabot-search huggingface dataset:
Molecular Landscapes and Models of Acute Erythroleukemia
Authors: Alexandre Fagnan, Maria-Riera Piqué-Borràs, Samantha Tauchmann, Thomas Mercher, Juerg Schwaller
Journal: HemaSphere (2021)

Malignancies of the erythroid lineage are rare but aggressive diseases. Notably, the first insights into their biology emerged over half a century ago from avian and murine tumor viruses-induced erythroleukemia models providing the rationale for several transgenic mouse models that unraveled the transforming potential of signaling effectors and transcription factors in the erythroid lineage. More recently, genetic roadmaps have fueled efforts to establish models that are based on the epigenomic lesions observed in patients with erythroid malignancies. These models, together with often unexpected erythroid phenotypes in genetically modified mice, provided further insights into the molecular mechanisms of disease initiation and maintenance. Here, we review how the increasing knowledge of human erythroleukemia genetics combined with those from various mouse models indicate that the pathogenesis of the disease is based on the interplay between signaling mutations, impaired TP53 function, and altered chromatin organization. These alterations lead to aberrant activity of erythroid transcriptional master regulators like GATA1, indicating that erythroleukemia will most likely require combinatorial targeting for efficient therapeutic interventions.
心臓肥大において,小コンダクタンスCa2+-活性化K+電流はCa2+/カルモジュリン依存性蛋白質キナーゼIIを経てアップレギュレートされる
Authors: Mizukami Kazuya, Yokoshiki Hisashi, Mitsuyama Hirofumi, Watanabe Masaya, Temma Taro, Takada Shingo, Tsutsui Hiroyuki
Journal: Circulation (2015)
Gremlin 1+ fibroblastic niche maintains dendritic cell homeostasis in lymphoid tissues
Authors: Varun N. Kapoor, Sören Müller, Shilpa Keerthivasan, Markus Brown, Cecile Chalouni, Elaine E. Storm, Alessandra Castiglioni, Ryan Lane, Maximilian Nitschke, Claudia X. Dominguez, Jillian L. Astarita, Akshay T. Krishnamurty, Catherine B. Carbone, Yasin Senbabaoglu, Amber W. Wang, Xiumin Wu, Viviana Cremasco, Merone Roose-Girma, Lucinda Tam, Jonas Doerr, Mark Z. Chen, Wyne P. Lee, Zora Modrusan, Yeqing Angela Yang, Richard Bourgon, Wendy Sandoval, Andrey S. Shaw, Frederic J. de Sauvage, Ira Mellman, Christine Moussion, Shannon J. Turley
Journal: Nature Immunology (2021)
CHARACTERIZING THE ANATOMIC SPECTRUM, SURGICAL TREATMENT, AND LONG-TERM CLINICAL OUTCOMES FOR 131 PATIENTS WITH SHONE’S COMPLEX
Authors: Tara Karamlou, Leah Lee, Naseeb Shaheen, Munir Ahmad, Robert Stewart, Gosta Pettersson, Hani Najm
Journal: Journal of the American College of Cardiology (2021)
SHOULD MOBILE TELEMETRY MONITORING OR IMPLANTABLE LOOP RECORDERS BE UTILIZED FOR EARLY DETECTION OF SILENT ATRIAL ARRHYTHMIAS IN PATIENTS WITH CRYPTOGENIC STROKE?
Authors: Jonathan Krathen, Jian Liang Tan, Gilbert Essilfie, Matthew Ortman, John Andriulli, Andrea Russo
Journal: Journal of the American College of Cardiology (2021)
Lack of association between tumor necrosis factor-α inhibitor use and exacerbation of lupus erythematosus: A retrospective cohort study
Authors: Michelle S. Min, Bina Kassamali, Daniel R. Mazori, Olivia Gizelis, Morgan Schaefer, Allen Ho, Joseph F. Merola, Gabriela Cobos, Avery H. LaChance, Ruth Ann Vleugels
Journal: Journal of the American Academy of Dermatology (2021)
The impact of the COVID‐19 pandemic on skin cancer incidence and treatment in England, 2020
Authors: Z. C. Venables, S. Ahmed, T. O. Bleiker, J. Broggio, M. Kwiatkowska, N. J. Levell, G. W. M. Millington, L. Paley, E. Payne, C. M. Proby, S. Vernon, S. McPhail
Journal: British Journal of Dermatology (2021)
IN-HOSPITAL MORTALITY RISK PREDICTION FOR PERCUTANEOUS CORONARY INTERVENTIONS: AN UPDATED MODEL FROM THE NCDR CATHPCI REGISTRY
Authors: Yulanka Castro Dominguez, Karl Minges, Yongfei Wang, Robert McNamara, John Spertus, Gregory Dehmer, John Messenger, Nestor Mercado, Kim Lavin, Dominique Pierre, Connie Anderson, Kristina Blankinship, Julie Clary, Anwar Osborne, Jeptha Curtis, Matthew Cavender
Journal: Journal of the American College of Cardiology (2021)
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis
Authors: Kai-Uwe Eckardt, Rajiv Agarwal, Ahmad Aswad, Ahmed Awad, Geoffrey A. Block, Marcelo R. Bacci, Youssef M.K. Farag, Steven Fishbane, Harold Hubert, Alan Jardine, Zeeshan Khawaja, Mark J. Koury, Bradley J. Maroni, Kunihiro Matsushita, Peter A. McCullough, Eldrin F. Lewis, Wenli Luo, Patrick S. Parfrey, Pablo Pergola, Mark J. Sarnak, Bruce Spinowitz, James Tumlin, Dennis L. Vargo, Kimberly A. Walters, Wolfgang C. Winkelmayer, Janet Wittes, Rafal Zwiech, Glenn M. Chertow
Journal: New England Journal of Medicine (2021)

Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, a class of compounds that stimulate endogenous erythropoietin production.We conducted two randomized, open-label, noninferiority phase 3 trials to evaluate the safety and efficacy of vadadustat, as compared with darbepoetin alfa, in patients with anemia and incident or prevalent dialysis-dependent chronic kidney disease (DD-CKD). The primary safety end point, assessed in a time-to-event analysis, was the first occurrence of a major adverse cardiovascular event (MACE, a composite of death from any cause, a nonfatal myocardial infarction, or a nonfatal stroke), pooled across the trials (noninferiority margin, 1.25). A key secondary safety end point was the first occurrence of a MACE plus hospitalization for either heart failure or a thromboembolic event. The primary and key secondary efficacy end points were the mean change in hemoglobin from baseline to weeks 24 to 36 and from baseline to weeks 40 to 52, respectively, in each trial (noninferiority margin, -0.75 g per deciliter).A total of 3923 patients were randomly assigned in a 1:1 ratio to receive vadadustat or darbepoetin alfa: 369 in the incident DD-CKD trial and 3554 in the prevalent DD-CKD trial. In the pooled analysis, a first MACE occurred in 355 patients (18.2%) in the vadadustat group and in 377 patients (19.3%) in the darbepoetin alfa group (hazard ratio, 0.96; 95% confidence interval [CI], 0.83 to 1.11). The mean differences between the groups in the change in hemoglobin concentration were -0.31 g per deciliter (95% CI, -0.53 to -0.10) at weeks 24 to 36 and -0.07 g per deciliter (95% CI, -0.34 to 0.19) at weeks 40 to 52 in the incident DD-CKD trial and -0.17 g per deciliter (95% CI, -0.23 to -0.10) and -0.18 g per deciliter (95% CI, -0.25 to -0.12), respectively, in the prevalent DD-CKD trial. The incidence of serious adverse events in the vadadustat group was 49.7% in the incident DD-CKD trial and 55.0% in the prevalent DD-CKD trial, and the incidences in the darbepoetin alfa group were 56.5% and 58.3%, respectively.Among patients with anemia and CKD who were undergoing dialysis, vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations. (Funded by Akebia Therapeutics and Otsuka Pharmaceutical; INNO2VATE ClinicalTrials.gov numbers, NCT02865850 and NCT02892149.).
Indole-3-carbinol (I3C) reactives p16 in pancreatic cancer cells through hypomethylation
Authors: Beverly Lyn-Cook, Aaron Haefele, Beverly Word, George Hammons
Journal: Cancer Research (2008)

2606  Pancreatic cancer is the fourth cause of death in the U.S. Due to its aggressive and resistance characteristics, prognosis is often fatal. Inactivation of tumor suppressor genes such as p53 and p16 early in the carcinogenesis process allows the selective advantage of other genomic changes and damage to occur, which further contributes to its progression. p16 inactivation through promoter hypermethylation is an early event in this process. PCR analyses of pancreatic cancer cells (MIA PaCa-2) treated with 1, 10 or 100 μM of I3C demonstrated reactivation of p16 at 10 or 100 μM, both at 24 and 48 hrs. p16 was not expressed in the untreated control. Methylated-sensitive-PCR (MSP) analyses demonstrated that indole-3-carbinol unmethylated the promoter region of p16, which was methylated in the untreated control. A positive control using 5-azacytidine also reactivated p16 at 48 hrs, but not 24 hrs. Recent data published in our laboratory demonstrated that I3C significantly decreased the expression of DNA methyltransferases (Haefele, et.al., International J Cancer Prev., 2(4):245-255, 2007). This study showed the potential use of the dietary agent, I3C, as a hypomethylating agent in chemopreventive or therapeutic strategies for pancreatic cancer.
Zn‐MOF Encapsulated Antibacterial and Degradable Microneedles Array for Promoting Wound Healing
Authors: Shun Yao, Junjie Chi, Yuetong Wang, Yuanjin Zhao, Yuan Luo, Yongan Wang
Journal: Advanced Healthcare Materials (2021)

An infected skin wound caused by external injury remains a serious challenge in clinical practice. Wound dressings with the properties of antibacterial activity and potent regeneration capacity are highly desirable for wound healing. In this paper, a degradable, ductile, and wound-friendly Zn-MOF encapsulated methacrylated hyaluronic acid (MeHA) microneedles (MNs) array is fabricated through the molding method for promoting wound healing. Due to the damage capability against the bacteria capsule and oxidative stress of the zinc ion released from the Zn-MOF, such MNs array presents excellent antibacterial activity, as well as considerable biocompatibility. Besides, the degradable MNs array composed of photo-crosslinked MeHA possesses the superior capabilities to continuously and steadily release the loaded active ingredients and avoid secondary damage to the wound. Moreover, the low molecular weight hyaluronic acid (HA) generated by hydrolysis of MeHA is also conducive to tissue regeneration. Benefiting from these features, it has been demonstrated that the Zn-MOF encapsulated degradable MNs array can dramatically accelerate epithelial regeneration and neovascularization. These results indicate that the combination of MOFs and degradable MNs array is of great value for promoting wound healing.
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Authors: Laith J. Abu-Raddad, Hiam Chemaitelly, Adeel A. Butt
Journal: New England Journal of Medicine (2021)

Efficacy of the BNT162b2 mRNA Vaccine in Qatar As of March 31, 2021, more than 265,000 people in Qatar had received both doses of the BNT162b2 vaccine. Viral sequencing indicated that 50.0% of infe...
Metabolic bifunctionality of Rv0812 couples folate and peptidoglycan biosynthesis in <i>Mycobacterium tuberculosis</i>
Authors: Katherine A. Black, Lijun Duan, Lungelo Mandyoli, Bruna P. Selbach, Weizhen Xu, Sabine Ehrt, James C. Sacchettini, Kyu Y. Rhee
Journal: The Journal of Experimental Medicine (2021)

Comparative sequence analysis has enabled the annotation of millions of genes from organisms across the evolutionary tree. However, this approach has inherently biased the annotation of phylogenetically ubiquitous, rather than species-specific, functions. The ecologically unusual pathogen Mycobacterium tuberculosis (Mtb) has evolved in humans as its sole reservoir and emerged as the leading bacterial cause of death worldwide. However, the physiological factors that define Mtb’s pathogenicity are poorly understood. Here, we report the structure and function of a protein that is required for optimal in vitro fitness and bears homology to two distinct enzymes, Rv0812. Despite diversification of related orthologues into biochemically distinct enzyme families, rv0812 encodes a single active site with aminodeoxychorismate lyase and D–amino acid transaminase activities. The mutual exclusivity of substrate occupancy in this active site mediates coupling between nucleic acid and cell wall biosynthesis, prioritizing PABA over D-Ala/D-Glu biosynthesis. This bifunctionality reveals a novel, enzymatically encoded fail-safe mechanism that may help Mtb and other bacteria couple replication and division.
Genetic impacts on DNA methylation: research findings and future perspectives
Authors: Sergio Villicaña, Jordana T. Bell
Journal: Genome biology (2021)

Abstract Multiple recent studies highlight that genetic variants can have strong impacts on a significant proportion of the human DNA methylome. Methylation quantitative trait loci, or meQTLs, allow for the exploration of biological mechanisms that underlie complex human phenotypes, with potential insights for human disease onset and progression. In this review, we summarize recent milestones in characterizing the human genetic basis of DNA methylation variation over the last decade, including heritability findings and genome-wide identification of meQTLs. We also discuss challenges in this field and future areas of research geared to generate insights into molecular processes underlying human complex traits.
OUTCOMES OF PATIENTS WITH SHOCK AND PULMONARY EMBOLISM UNDERGOING PERCUTANEOIUS MECHANICAL THROMBECTOMY WITH INARI FLOWTRIEVER SYSTEM COMPARED WITH SYSTEMIC THROMBOLYSIS
Authors: Raad Al Tamimi, Yasser Al-Khadra, Basma Al-bast, Radhika Deshpande, Venkata Missula, Prashanth Singanallur, Nour Albast, Manasik Abdu, Abdul Moiz Hafiz
Journal: Journal of the American College of Cardiology (2021)
Correspondence on ‘EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs’
Authors: Serena Bugatti, Silvia Balduzzi, Ludovico De Stefano, Antonio Manzo, Blerina Xoxi, Laura Bogliolo, Sara Monti, Paolo Delvino, Carlomaurizio Montecucco
Journal: Annals of the Rheumatic Diseases (2021)

In light of their increased risk of worst outcomes following COVID-19 infection, patients with rheumatic and musculoskeletal diseases (RMDs) on immunosuppressive therapy, including systemic glucocorticoids, biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs), represent a vulnerable population which should be prioritised to receive vaccination. Controlled data on the effectiveness and safety of different COVID-19 vaccines on patients with RMD are not available yet. However, rheumatology providers and health professionals should be ready to offer timely guidance for the optimal use of vaccines for patients on immunomodulatory drugs. Based on the long-time experience with other non-live vaccines, the COVID-19 Task Force of the European League Against Rheumatisms (EULAR) first delivered a preliminary set of information in December 2020.1 Overall, it is expected that the safety and immunogenicity of COVID-19 vaccines for most of the DMARDs will be comparable with that registered for the general population,2–4 so that postponing vaccination pending more information appears unjustified. A number of independent surveys have however alarmingly reported that, among patients with RMD, potential acceptance of COVID-19 vaccines may not exceed 60%, without apparent differences in relation to specific diseases, comorbidities and type of medication.5–8 Strategies to effectively engage high-risk patients with RMD into vaccination programmes are therefore urgently needed.

Starting from 19 March 2021, rheumatologists of the IRCCS Policlinico San Matteo University Hospital of Pavia, Italy, have been actively involved in the vaccination campaign by personally contacting, booking and administering COVID-19 vaccines to patients with RMD on b/tsDMARDs followed at …
Statin Prescribing and Dosing—Failure Has Become an Option—Reply
Authors: Srinath Adusumalli, Mitesh S. Patel
Journal: JAMA Cardiology (2021)

In Reply We thank Mark et al for their comments regarding our work on statin prescription decision support embedded within the electronic health record.1 We appreciate their interest and the perspective they have added, particularly regarding the important topic of statin intolerance and resistance.
P08.37 Analyzing the interactions of mRNAs, miRNAs, lncRNAs and circRNAs to predict competing endogenous RNA networks in glioblastoma
Authors: Q. Mao, Xiang Yuan
Journal: Neuro-Oncology (2017)

BACKGROUND: Cross-talk between competitive endogenous RNAs (ceRNAs) may play a critical role in revealing potential mechanisms of tumor development and physiology. Glioblastoma is the most common type of malignant primary brain tumor, and the mechanisms of tumor genesis and development in glioblastoma are unclear. METHODS: Here, to investigate the role of non-coding RNAs and the ceRNA network in glioblastoma, we performed paired-end RNA sequencing and microarray analyses to obtain the expression profiles of mRNAs, lncRNAs circRNAs and miRNAs. Results: We identified that the expression of 501 lncRNAs, 1789 mRNAs, 2038 circRNAs and 143 miRNAs were often altered between glioblastoma and matched normal brain tissue. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed on these differentially expressed mRNAs and miRNA-mediated target genes of lncRNAs and circRNAs. Furthermore, we used a multi-step computational framework and several bioinformatics methods to construct a ceRNA network combining mRNAs, miRNAs, lncRNAs and circRNA, based on co-expression analysis between the differentially expressed RNAs. CONCLUSION: We identified that plenty of lncRNAs, CircRNAs and their downstream target genes in the ceRNA network are related to glutamatergic synapse, suggesting that glutamate metabolism is involved in glioma biological functions. Our results will accelerate the understanding of tumorigenesis, cancer progression and even therapeutic targeting in glioblastoma.
MEASUREMENT OF THREE-DIMENSIONAL (3D) MITRAL VALVE AREA IN PATIENTS WITH MITRAL ANNULAR CALCIFICATION BY TRANSTHORACIC ECHOCARDIOGRAPHY
Authors: Aashish Gupta, Ivana Okor, Sergey Kachur, Rikin Kadakia, Michael Stone, Jessica Morris, Daniel Morin, Yvonne Gilliland, Gregg Pressman, Salima Qamruddin
Journal: Journal of the American College of Cardiology (2021)
IMPORTANCE OF THE ELECTROCARDIOGRAPHIC STRAIN PATTERN IN PATIENTS UNDERGOING TAVI
Authors: Stergios Soulaidopoulos, Maria Drakopoulou, Konstantinos Stathogiannis, George Oikonomou, Padelis Toskas, Maria Xanthopoulou, Andreas Synetos, George Latsios, Antonis Karanasos, Angelos Papanikolaou, Skevos Sideris, Konstantinos Tsioufis, Konstantinos Toutouzas
Journal: Journal of the American College of Cardiology (2021)
BURDEN OF MENTAL HEALTH DIAGNOSES IN HOSPITALIZATIONS IN ADULTS WITH CONGENITAL HEART DISEASE IN THE STATE OF TEXAS: A 10-YEAR REVIEW
Authors: Amelia Mercado, Andrew Well, Alexandra Lamari-Fisher, Michelle Mizrahi, Gregory Johnson, Hanoch Patt, Carlos Mery, Charles Fraser, Ziv Beckerman
Journal: Journal of the American College of Cardiology (2021)
Abstract 16083: Risk of Preserved versus Reduced Ejection Fraction in Women With and Without History of Breast Cancer: The Pathways Heart Study
Authors: Jamal S Rana, Heather Greenlee, Richard Cheng, Cecile A Laurent, Hanjie Shen, Janise M Roh, Valerie S Lee, Romain S Neugebauer, Dawn L Hershman, Lawrence H Kushi, Mai N Nguyen-huynh, Carlos Iribarren, Marilyn L Kwan
Journal: Circulation (2020)

Introduction: Incidence of heart failure (HF), specifically with preserved ejection fraction (HFpEF), is rising in the general population, yet is understudied. To provide a population-based estimate of HF in breast cancer (BC) survivors, we compared risk of HF in women with and without BC history in the Kaiser Permanente Northern California (KPNC) integrated health system. Methods: Data were extracted from KPNC electronic health records. All invasive BC cases diagnosed from 2005-2013 were identified and matched 1:5 with non-BC controls on birth year, race/ethnicity, and KPNC membership at BC diagnosis. Cox regression models assessed the hazard of HF by EF status: HFpEF (EF ≥ 45%), HF with reduced EF (HFrEF; EF &lt; 45%), and unknown EF. Women with prior history of HF were excluded. Models were adjusted for factors known to affect BC risk or CVD and for prevalent CVD at BC diagnosis. We also examined case subgroups who received cardiotoxic chemotherapy, left-sided radiation therapy, and/or endocrine therapy, versus their controls. Results: A total of 14,804 women diagnosed with invasive BC and with no history of HF were identified and matched to 74,034 women without BC history. Women were on average 61 years at BC diagnosis and 65% white. Women with HFpEF were older and more likely to have hypertension (p&lt;0.05). Among all cases vs. controls, there was increased risk of HFrEF (HR: 1.5, 95% CI: 1.18, 1.98) but not HFpEF or unknown EF (figure). Compared to their controls, women treated with chemotherapy were more than 3-times likely to develop HFrEF (HR: 3.26, 95% CI: 2.2, 4.8) and more than 1.5-times likely to develop HFpEF (HR=1.61, 95% CI: 1.15, 2.24). Women who received left-sided radiation therapy had nearly double the risk of developing HFrEF (HR=1.85, 95% CI: 1.20, 2.84). No associations were found among women who received endocrine therapy. Conclusions: Increased surveillance is warranted for women with BC receiving cardiotoxic chemotherapy for development of both HFrEF and HFpEF.
Evaluation of Topical Corticosteroid Use in Pregnancy and Risk of Newborns Being Small for Gestational Age and Having Low Birth Weight
Authors: Niklas Worm Andersson, Lone Skov, Jon Trærup Andersen
Journal: JAMA Dermatology (2021)

Topical corticosteroids are frequently used during pregnancy. Limited data have raised concerns about an increased risk of the newborn being small for gestational age (SGA) and having low birth weight, in particular with use of potent to very potent agents during pregnancy.To evaluate whether topical corticosteroid use in pregnancy is associated with increased risks of SGA and low birth weight.From a source cohort of 1.1 million pregnancies with individual-level informed data from various registries, this nationwide cohort study identified topical corticosteroid-exposed pregnancies in Denmark from January 1, 1997, to December 31, 2016, for a total of 60 497, that were matched with 241 986 unexposed pregnancies on the basis of propensity scores, including a wide set of baseline characteristics. Data analysis was performed from September 8, 2020, to February 23, 2021.Filled prescriptions for topical corticosteroids during pregnancy.Primary outcomes were SGA and low birth weight. Association between outcomes and exposure was assessed by relative risk ratios (RRs) and absolute risk differences (ARDs).Among the 60 497 matched pregnancies exposed to topical corticosteroids, 5678 (9.4%) of the delivered infants were born SGA compared with 22 634 infants (9.4%) among the matched unexposed pregnancies (RR, 1.00; 95% CI, 0.98-1.03 and ARD, 0.3; 95% CI, -2.3 to 2.9 per 1000 pregnancies). Low birth weight occurred in 2006 (3.3%) of the exposed pregnancies compared with 8675 (3.6%) of the unexposed pregnancies (RR, 0.92; 95% CI, 0.88-0.97 and ARD, -2.7; 95% CI, -4.3 to -1.1 per 1000 pregnancies). Exposure to potent to very potent topical corticosteroids at any amount was not associated with an increased risk of SGA (RR, 1.03; 95% CI, 0.99-1.07) or low birth weight (RR, 0.94; 95% CI, 0.88-1.00). Post hoc analyses did not find a significant increased risk among those receiving large amounts of potent to very potent topical corticosteroids (ie, >200 g throughout pregnancy) compared with unexposed pregnancies (RR, 1.17; 95% CI, 0.95-1.46 for SGA and RR 1.14; 95% CI, 0.81-1.60 for low birth weight).This large cohort study found no association between topical corticosteroid use in pregnancy and an increased risk of SGA or low birth weight. These results suggest that a moderate to large increase in the risk is unlikely, even when large amounts of potent to very potent topical corticosteroids are used in pregnancy.
ADIPOSE TISSUE ADIPOKINE EXPRESSION IS LINKED TO METABOLIC RISK IN OBESITY
Authors: Carine Hamo, Risa Wolf, Amelia Wallace, Alex Arking, Xin Chu, Roberta Florido, Justin Echouffo-Tcheugui, Mariam Meddeb, Kunihiro Matsushita, Gary Gerstenblith, Rexford Ahima, Craig Wood, Josef Coresh, Peter Benotti, G. William Wong, Chiadi Ndumele
Journal: Journal of the American College of Cardiology (2021)